CTLA4 and neoplasm: The requirement for induction of local Treg depletion within the tumor microenvironment to achieve therapeutic effects is inconsistent with another postulate of the checkpoint blockade hypothesis,1 which states that unlike anti-PD-1/PD-L1 antibodies, anti-CTLA-4 antibodies promote tumor rejection by preventing negative signaling in the peripheral lymphoid organs.